Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

European Journal of Endocrinology, Vol 133, Issue 4, 430-439
Copyright © 1995 by European Society of Endocrinology
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arosio, M
Right arrow Articles by Faglia, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arosio, M
Right arrow Articles by Faglia, G
Clinical Studies

Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group

M Arosio, S Macchelli, CM Rossi, G Casati, O Biella, and G Faglia

Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS, Italy.

Treatment of acromegaly is effective in reversing the reduced life-span of patients only when serum growth hormone (GH) concentrations are lowered to less than 2.5 micrograms/l. Usual treatments achieve this goal in no more than 50-60% of patients. The effects of octreotide were studied in a prospective, open label study with 68 acromegalic patients enrolled in 10 Italian centers. Octreotide was administered sc at a dose of 100 micrograms t.i.d. for 1 year. After 3 months of therapy, octreotide was effective in decreasing serum GH levels below 2.5 micrograms/l in 16 out of 64 acromegalic patients (25%). Fifteen of them had pretreatment GH levels below 25 micrograms/l. Insulin-like growth factor I (IGF-I) levels normalized in about 40% of patients. No further GH reduction was observed after 1 year of treatment. The presence of abnormal GH responses to thyrotropin-releasing hormone (TRH) and gonadotropin-releasing hormone was reduced from 54 to 24% and from 16 to 12%, respectively. Tumor shrinkage was observed in 50% of 26 non-irradiated patients after 12 months of treatment. Both basal and TRH-stimulated serum prolactin levels significantly decreased in the 11 hyperprolactinemic patients. Although serum thyrotropin, free triiodothyronine and free thyroxine concentrations were not modified, a significant reduction of thyrotropin response to TRH was observed in the 9th month of therapy. In non-diabetic patients, an increase of mean blood glucose levels without modifications of fasting morning concentrations was found. About one-quarter of the patients with overt diabetes mellitus had an impairment of their metabolic control. Main clinical symptoms of acromegaly improved in 70-80% of patients.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
S.-C. Hua, Y.-H. Yan, and T.-C. Chang
Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly
Eur. J. Endocrinol., December 1, 2006; 155(6): 831 - 837.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao, R. Pivonello, R. S. Auriemma, F. Briganti, M. Galdiero, F. Tortora, F. Caranci, S. Cirillo, and G. Lombardi
Predictors of Tumor Shrinkage after Primary Therapy with Somatostatin Analogs in Acromegaly: A Prospective Study in 99 Patients
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2112 - 2118.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Colao, R. Pivonello, R. S Auriemma, M. C. De Martino, M. Bidlingmaier, F. Briganti, F. Tortora, P. Burman, I. A Kourides, C. J Strasburger, et al.
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Eur. J. Endocrinol., March 1, 2006; 154(3): 467 - 477.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G M Besser, P Burman, and A F Daly
Predictors and rates of treatment-resistant tumor growth in acromegaly
Eur. J. Endocrinol., August 1, 2005; 153(2): 187 - 193.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. S. Bevan
The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1856 - 1863.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. Colao, D. Ferone, P. Marzullo, and G. Lombardi
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
Endocr. Rev., February 1, 2004; 25(1): 102 - 152.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Baldelli, A. Colao, P. Razzore, M.-L. Jaffrain-Rea, P. Marzullo, E. Ciccarelli, E. Ferretti, D. Ferone, D. Gaia, F. Camanni, et al.
Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg)
J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4099 - 4103.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. K. Flogstad, J. Halse, S. Bakke, I. Lancranjan, P. Marbach, Ch. Bruns, and J. Jervell
Sandostatin LAR in Acromegalic Patients: Long Term Treatment
J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 23 - 28.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 European Society of Endocrinology.